



## Child ADHD Medication Follow-up (*Initiation*)

Measure Type: HEDIS (claims) / Age Cohort: 6–12 years of age as of the Index Prescription Start Date (IPSD)

### *Measure Definition*

Percent of patients\* with an ambulatory prescription dispensed for ADHD medication, who had one follow-up visit with practitioner with prescribing authority\*\* during the 30-day Initiation Phase

\* **Patients** are identified as “new”, dispensed an ADHD medication for the first time or “existing”, patient has a history of taking ADHD medication but had no ADHD medication dispensed for either new or refill prescription in a period of 120 days or more.

\*\***Prescribing Authority:** A practitioner with prescribing privileges, including physicians, nurse practitioners, physician assistants who have the authority to prescribe medications

### *Documentation Required*

Index visit resulting with ADHD diagnosis and ADHD medication prescribed ([Medication List](#))

- Follow-up visit within 30 days of the index visit

Applicable Follow-up Visit CPT/HCPCS Codes: 90791 – 90792, 90801 – 90829, 90832 – 90840, 90845, 90847, 90849, 90853, 90857, 90862, 90875, 90876, 96150 – 96154, 98960 – 98962, 99078, 99201-99205, 99211 – 99215, 99217 – 99223, 99231 – 99233, 99238 – 99239, 99241 – 99245, 99251 – 99255, 99341 – 99350, 33891 – 99394, 99401 – 99404, 99411 – 99412, 99510

### *Role of Care Management*

- Ensure prescription fill
- Ensure follow-up visit within 30 days
- Identify & address barriers to adherence

### *Role of PCP Practice*

- Schedule follow-up visit within 30 days of index visit OR referral to behavioral health prescribing provider
- Visit reminder message to the patient



## Child ADHD Medication Follow-up (*Continuation*)

Measure Type: HEDIS (claims) / Age Cohort: 6–12 years of age as of the Index Prescription Start Date (IPSD)



### *Measure Definition*

Percent of patients with an ambulatory prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the first follow-up visit in the Initiation Phase, had at **least two follow-up visits with a practitioner** within 270 days (9 months) after the Initiation Phase ended.

### *Documentation Required*

Index visit resulting with ADHD diagnosis and ADHD medication prescribed ([Medication List](#))

- One follow-up visit within 30 days of the index visit
- Two follow-up visits after the initiation phase but within 270 days
- Refill of prescriptions

Applicable Follow-up Visit CPT/HCPCS Codes: 90791 – 90792, 90801 – 90829, 90832 – 90840, 90845, 90847, 90849, 90853, 90857, 90862, 90875, 90876, 96150 – 96154, 98960 – 98962, 99078, 99201-99205, 99211 – 99215, 99217 – 99223, 99231 – 99233, 99238 – 99239, 99241 – 99245, 99251 – 99255, 99341 – 99350, 33891 – 99394, 99401 – 99404, 99411 – 99412, 98966 – 98968, 99441 – 99443, 99510, G0155, G0176, G0177, G0409 – G0411, G0463, H0002, H0004, H0031, H0034 – H0037, H0039, H0040, H2000, H2001, H2010 – H2020, M0064, S0201, S9480, S9484, S9485, T1015

### *Role of Care Management*

- Verify diagnosis with patient
- Ensure consistent refills
- Ensure follow-up visits
- Identify & address barriers to adherence

### *Role of PCP Practice*

- Schedule two additional follow-up visits within 270 days OR ensure two additional follow-up visits with behavioral health provider
- Visit reminder message to the patient



<b>Measure</b>	<b>Medication List</b>
<p>Child ADHD Medication Follow-up</p> <p><a href="#">Back to Measure</a> (Initiation)</p> <p><a href="#">Back to Measure</a> (Continuation)</p>	<p>Amphetamine-dextroamphetamine, Dexmethylphenidate, Dextroamphetamine, Lisdexamfetamine, Methylphenidate, Methamphetamine, Clonidine, Guanfacine, Atomoxetine</p>
<p>Diabetes Screening for People with Schizophrenia or Bipolar Disease who are Using Antipsychotic Medication</p> <p><a href="#">Back to Measure</a></p>	<p>Aripiprazole, Asenapine, Clozapine, Haloperidol, Iloperidone, Loxapine, Lurisdone, Molindone, Olanzapine, Paliperidone, Pimozide, Quetiapine, Quetiapine fumarate, Risperidone, Ziprasidone,</p> <p>Chlorpromazine, Fluphenazine, Perphenazine, Perphenazine-amitriptyline, Prochlorperazine, Thioridazine, Trifluoperazine, Fluoxetine-olanzapine, Thiothixene, Fluphenazine decanoate, Haloperidol decanoate, Paliperidone palmitate</p>